NOX

O-I Glass Sustainably Transformed and Expanded Zipaquira, Colombia, Plant

Retrieved on: 
Wednesday, April 17, 2024
Corporate Affairs, CO2, Glass, Investment, Atmosphere, Food, Safety, NOX

PERRYSBURG, OH/ZIPAQUIRA, COLOMBIA, April 17, 2024 (GLOBE NEWSWIRE) -- O-I Glass, Inc. (“O-I Glass” or “O-I”) recently completed a major transformation of its Zipaquira, Colombia manufacturing site investing approximately $120 Million to upgrade the sustainability, flexibility, and productivity of the plant.

Key Points: 
  • PERRYSBURG, OH/ZIPAQUIRA, COLOMBIA, April 17, 2024 (GLOBE NEWSWIRE) -- O-I Glass, Inc. (“O-I Glass” or “O-I”) recently completed a major transformation of its Zipaquira, Colombia manufacturing site investing approximately $120 Million to upgrade the sustainability, flexibility, and productivity of the plant.
  • This is consistent with O-I's sustainability strategy, the company’s ongoing investments into plant upgrades, and aligned with its previously announced capital spending plan.
  • A new furnace has been installed that incorporates well-proven oxy/fuel combustion and waste heat recovery technology.
  • “We are proud of our advancements in Zipaquira, upgrading the sustainability, technology innovation, safety, quality and productivity of our plant” said Alvaro Suarez, Managing Director for O-I Andean Region.

Quectel to Showcase Latest IoT Solutions at Embedded World 2024

Retrieved on: 
Monday, April 8, 2024
Telecommunications, Satellite, Software, Networks, Data Management, Technology, IOT (Internet of Things), Mobile, Wireless, Temperature, MiFi, Certification, 4G, New product development, Original equipment manufacturer, Wi-Fi, Feminism and modern architecture, Humidity, Iris, App Store (iOS/iPadOS), ODM, MikroTik, Running, ZCS, AWS, NFC, COV, NOX, Gateway, CO2, Ecosystem, CSO, Data management, HUD, GNSS, Mobile phone

Quectel Wireless Solutions, a global IoT solutions provider, is pleased to be showcasing some its industry leading IoT connectivity solutions and technologies, catering to various industries and applications at Embedded World 2024 in Nürnberg.

Key Points: 
  • Quectel Wireless Solutions, a global IoT solutions provider, is pleased to be showcasing some its industry leading IoT connectivity solutions and technologies, catering to various industries and applications at Embedded World 2024 in Nürnberg.
  • In addition, Zeljko Maric, Product Development Manager at Quectel, will be participating in a panel session centered on IoT Modem Reference Design or IoT SoC Modules Modem for Embedded Designers.
  • "We are excited to participate in Embedded World 2024 and showcase our latest innovations in IoT connectivity," said Norbert Muhrer, President and CSO, Quectel Wireless Solutions.
  • "As a leading provider of IoT modules, Quectel is dedicated to empowering businesses worldwide with reliable, secure and innovative connectivity solutions.

Quectel Showcases 5G IoT Innovation at MWC Barcelona 2024

Retrieved on: 
Monday, February 26, 2024
Technology, Mobile, Wireless, Audio, Video, Apps, Applications, 5G, Payments, Telecommunications, IOT (Internet of Things), Software, Networks, Internet, Hardware, Consumer Electronics, Satellite, Bluetooth, ARM, BSI, HUD, Redcap, ODM, Android, NTN, MikroTik, Modem, IEEE 802.11be, App Store (iOS/iPadOS), Particle, ZCS, MWC, Data-rate units, COV, Motorcycle, Bit, MIMO, TCU, AMD, NFC, LTE, CPE, NOX, Original equipment manufacturer, Life, PC, Safety, WOS, Humidity, CO2, SOC, CSO, Mobile World Congress, Iris, Intel, BLE, GNSS, Temperature, Internet of things, LoRa, Linux, Connectivity, Mobile phone

Quectel Wireless Solutions, a global IoT solutions provider, is pleased to announce its participation in the Mobile World Congress (MWC) Barcelona 2024, where it will showcase its IoT solutions alongside collaborations with industry-leading partners.

Key Points: 
  • Quectel Wireless Solutions, a global IoT solutions provider, is pleased to announce its participation in the Mobile World Congress (MWC) Barcelona 2024, where it will showcase its IoT solutions alongside collaborations with industry-leading partners.
  • "Our presence at MWC Barcelona 2024 together with our customers’ applications is a testament to our dedication to innovation and our customers' trust in us to lead the way in 5G technology."
  • MikroTik Chateau 5G Router: Quectel and MikroTik have teamed up to present the Chateau 5G Router, a device that epitomizes the fusion of sophisticated design and powerful 5G connectivity.
  • Attendees can visit the Quectel booth in Hall Five, stand 5A19 at MWC Barcelona 2024 to experience these innovations first-hand and to discuss how 5G technology can revolutionize their businesses and everyday life.

Calliditas Therapeutics appoints Maria Törnsén as President North America

Retrieved on: 
Sunday, January 7, 2024
NOX, Immunoglobulin A, Risk, FDA, Sustainability, Capsule, Person, Sarepta Therapeutics, Therapy, IgA nephropathy, Growth, SVP, Patient, CALT, Pharmaceutical industry

STOCKHOLM, Jan. 7, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today announced that Maria Törnsén has been appointed to the position of President North America.

Key Points: 
  • STOCKHOLM, Jan. 7, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today announced that Maria Törnsén has been appointed to the position of President North America.
  • Maria Törnsén has broad commercial leadership experience having spent more than 20 years in the biopharma industry in senior commercial roles.
  • Most recently Ms Törnsén held the position of Chief Commercial Officer at Passage Bio, prior to which she was SVP General Manager US at Sarepta Therapeutics.
  • "We are pleased to welcome Ms Törnsén to the executive management team as President of our US operations.

Calliditas Therapeutics appoints Maria Törnsén as President North America

Retrieved on: 
Sunday, January 7, 2024
NOX, Immunoglobulin A, Risk, FDA, Sustainability, Capsule, Person, Sarepta Therapeutics, Therapy, IgA nephropathy, Growth, SVP, Patient, CALT, Pharmaceutical industry

STOCKHOLM, Jan. 7, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today announced that Maria Törnsén has been appointed to the position of President North America.

Key Points: 
  • STOCKHOLM, Jan. 7, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today announced that Maria Törnsén has been appointed to the position of President North America.
  • Maria Törnsén has broad commercial leadership experience having spent more than 20 years in the biopharma industry in senior commercial roles.
  • Most recently Ms Törnsén held the position of Chief Commercial Officer at Passage Bio, prior to which she was SVP General Manager US at Sarepta Therapeutics.
  • "We are pleased to welcome Ms Törnsén to the executive management team as President of our US operations.

Calliditas Interim Report January - September 2023

Retrieved on: 
Tuesday, November 7, 2023
International Symposium on Endovascular Therapy, FDA, Operating cost, PDUFA, SEK, Nephrology, Magazine, ASN, NOX, USD, CMO, IgA nephropathy, Alport syndrome, Rare-earth element, Cryptocurrency, Pharmaceutical industry, Alport, EU, Lancet

Operating loss amounted to SEK 159.6 million and SEK 36.2 million for the three months ended September 30, 2023, and 2022, respectively.

Key Points: 
  • Operating loss amounted to SEK 159.6 million and SEK 36.2 million for the three months ended September 30, 2023, and 2022, respectively.
  • Significant Events in Q3 2023, in Summary
    On July 13 Calliditas announced supportive interim data from Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib.
  • Calliditas invites investors, analysts and press to a presentation of the Quarterly Report 2023 at 14:30 pm.
  • Calliditas' CEO Renee Aguiar-Lucander will present the report together with CFO Fredrik Johansson, CMO Richard Philipson and President North America Andrew Udell.

Calliditas Interim Report January - September 2023

Retrieved on: 
Tuesday, November 7, 2023
International Symposium on Endovascular Therapy, FDA, Operating cost, PDUFA, SEK, Nephrology, Magazine, ASN, NOX, USD, CMO, IgA nephropathy, Alport syndrome, Rare-earth element, Cryptocurrency, Pharmaceutical industry, Alport, EU, Lancet

Operating loss amounted to SEK 159.6 million and SEK 36.2 million for the three months ended September 30, 2023, and 2022, respectively.

Key Points: 
  • Operating loss amounted to SEK 159.6 million and SEK 36.2 million for the three months ended September 30, 2023, and 2022, respectively.
  • Significant Events in Q3 2023, in Summary
    On July 13 Calliditas announced supportive interim data from Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib.
  • Calliditas invites investors, analysts and press to a presentation of the Quarterly Report 2023 at 14:30 pm.
  • Calliditas' CEO Renee Aguiar-Lucander will present the report together with CFO Fredrik Johansson, CMO Richard Philipson and President North America Andrew Udell.

Calliditas Presents Additional Data Analyses from the NefIgArd Phase 3 trial at the American Society of Nephrology (ASN) Kidney Week 2023

Retrieved on: 
Tuesday, November 7, 2023
Science, Glomerulosclerosis, B-cell activating factor, DSM-IV codes, Ramipril, Biomarker, Rare, Budesonide, EGFR, Kidney, Person, CD23, Fibrosis, GALT, ACE, Protein, Society, American Society of Nephrology, BAFF, CD30, Urine, ASN, Record, Serum, CET, NOX, Immunoglobulin A, CALT, Histology, Patient, CD27, Alport syndrome, Pharmaceutical industry, Vaccine, IgA nephropathy, Publication, Alport

The Phase 3 double-blind, randomized NefIgArd study evaluated the impact of Nefecon, a novel targeted-release formulation of budesonide, vs placebo on eGFR in adults with IgAN.

Key Points: 
  • The Phase 3 double-blind, randomized NefIgArd study evaluated the impact of Nefecon, a novel targeted-release formulation of budesonide, vs placebo on eGFR in adults with IgAN.
  • The 2-year study period consisted of nine months of treatment with Nefecon (16 mg/day) or placebo, followed by a 15-month follow-up period off the study drug.
  • Levels of secretory IgA and fatty acid-binding protein, a gut permeability marker, were unchanged at these same time points.
  • Together, these biomarker data add to the body of evidence supporting a disease-modification effect for Nefecon, including modulation of immune complex formation.

Calliditas Presents Additional Data Analyses from the NefIgArd Phase 3 trial at the American Society of Nephrology (ASN) Kidney Week 2023

Retrieved on: 
Tuesday, November 7, 2023
Science, Glomerulosclerosis, B-cell activating factor, DSM-IV codes, Ramipril, Biomarker, Rare, Budesonide, EGFR, Kidney, Person, CD23, Fibrosis, GALT, ACE, Protein, Society, American Society of Nephrology, BAFF, CD30, Urine, ASN, Record, Serum, CET, NOX, Immunoglobulin A, CALT, Histology, Patient, CD27, Alport syndrome, Pharmaceutical industry, Vaccine, IgA nephropathy, Publication, Alport

The Phase 3 double-blind, randomized NefIgArd study evaluated the impact of Nefecon, a novel targeted-release formulation of budesonide, vs placebo on eGFR in adults with IgAN.

Key Points: 
  • The Phase 3 double-blind, randomized NefIgArd study evaluated the impact of Nefecon, a novel targeted-release formulation of budesonide, vs placebo on eGFR in adults with IgAN.
  • The 2-year study period consisted of nine months of treatment with Nefecon (16 mg/day) or placebo, followed by a 15-month follow-up period off the study drug.
  • Levels of secretory IgA and fatty acid-binding protein, a gut permeability marker, were unchanged at these same time points.
  • Together, these biomarker data add to the body of evidence supporting a disease-modification effect for Nefecon, including modulation of immune complex formation.

Novotech Releases In-Depth 2023 Global Clinical Trial Landscape Reports on Hemophilia and Primary Biliary Cholangitis

Retrieved on: 
Thursday, November 2, 2023
Female, Haemophilia B, United Kingdom, AAV, III, RNA, Cirrhosis, Ascending cholangitis, Health, Global Jurist of the Year Award, Research, PBC, Bile, FXR, Liver failure, NOX, Woman, Primary biliary cholangitis, Haemophilia A, Patient, Small RNA, Fine chemical, Pharmaceutical industry, Medical imaging, Haemophilia

BOSTON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Novotech, the leading Asia Pacific centred biotech CRO with global execution capabilities, today released the latest 2023 global clinical trial landscape reports on Primary Biliary Cholangitis (PBC) and Hemophilia .

Key Points: 
  • BOSTON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Novotech, the leading Asia Pacific centred biotech CRO with global execution capabilities, today released the latest 2023 global clinical trial landscape reports on Primary Biliary Cholangitis (PBC) and Hemophilia .
  • These reports provide up-to-date information on global clinical trial activity, shedding light on the regions that are witnessing the highest trial numbers and the reasons behind it.
  • As per the findings in the Primary Biliary Cholangitis – Global Clinical Trial Landscape report there have been approximately 140 active clinical trials focused on PBC since 2018.
  • In the Hemophilia Global Clinical Trial Landscape report, there has been a substantial increase in global clinical trials aimed at advancing hemophilia treatment since 2018.